CompaniesCLOV
S1Overview
CLOV
Clover Health
HealthcareMedicare AdvantageTurnaround
$3.10+3.3%
Market Cap
$1.50B
SEC 10-Q
P/E (TTM)
[awaiting: consensus]
via financials
Rev Growth YoY
62.0%
+62%SEC filing
Gross Margin
18.0%
SEC filing
FCF Yield
—
calculated
Upside to FV
—
vs fair value
Conviction
3/5Medicare Advantage insurer hitting its first profitable quarter — $749M revenue (+62%), SEC matter closed.
Research Depth
ScreeningDeep DiveFull Model
Updated 22d ago
S2Thesis
Clover Health is a tech-enabled Medicare Advantage insurer. Q1 2026 delivered $749M revenue (+62% YoY) and $27.3M net income — its first profitable quarter. The SEC investigation closed in Sept 2024 and a stale 66% data-conflict flag has been cleared. Phase 1 — promote pending margin durability.
Bull Case
[awaiting: bull — Phase 2]Bear Case
[awaiting: bear — Phase 2]S3Key Metrics
Market Cap
$1.50B
SEC 10-Q
Enterprise Value
$1.20B
calculated
Revenue (TTM)
$2.40B
SEC filing
P/E (TTM)
[awaiting: consensus]
via financials
Forward P/E
30.0×
consensus
P/S (TTM)
0.6×
via financials
P/B
2.5×
via financials
EV/EBITDA
[awaiting: calc]
calculated
PEG
—
calculated
Revenue Growth
62.0%
SEC filing
Gross Margin
18.0%
SEC filing
Operating Margin
2.0%
SEC filing
Net Margin
1.1%
SEC filing
Free Cash Flow
[awaiting: filing]
SEC filing
FCF Yield
—
calculated
Debt / Equity
0.1×
SEC filing
Current Ratio
1.4×
SEC filing
Short Interest
9.4%
exchange
Institutional Own.
[awaiting: 13F]
13F
Insider Own.
[awaiting: proxy]
proxy
Shares Out.
480.0M
SEC filing
Float
400.0M
exchange
S4Valuation
Price vs Fair Value
Valuation pending
Scenario fair-value range awaiting model.
DCF Summary
DCF awaiting Phase 2+
Discounted cash-flow model is built once research reaches Deep Dive.
Historical Multiples
Multiple history pending
This section is being deepened.
Peer Comparison
Peer set pending
Comparable companies awaiting selection.
S5Financials
Income statement pending
Awaiting SEC filing backfill.
Balance sheet pending
Awaiting SEC filing backfill.
Cash flow pending
Awaiting SEC filing backfill.
Phase 1.
S6Catalysts
Catalyst calendar pending
Upcoming events awaiting research.
S7Risks
Risk matrix pending
This section is being deepened.
S8Technical Snapshot
Technical snapshot pending
Price levels and indicators awaiting data.
S9Ownership & Insider Activity
Top Institutional Holders via 13F filings
13F holdings pending
Institutional holder detail awaiting filing.
Insider Activity
Insider transactions pending
This section is being deepened.
S10Peer Comparison
Peer set pending
Comparable companies awaiting selection.
S11Research Notes
2026-05-25Internal
First profitable quarter
$27.3M net income, first profitable quarter. Data-conflict flag was stale.